Detection method for detecting low-abundance myocardial MicroRNA-155 based on Janus platinum nano-enzyme enhanced tyramine signal amplification probe

The Janus platinum nanozyme-enhanced tyramide signal amplification probe method addresses the challenges of detecting low-abundance myocardial microRNA-155 by employing Janus platinum nanoparticles for sensitive and specific detection, achieving improved sensitivity and stability in microRNA-155 detection.

CN119061131APending Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE)
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411031225.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current methods for detecting low-abundance myocardial microRNA-155 face challenges such as high nonspecific adsorption, limited luminescence intensity, and inefficient signal amplification, particularly in tyramide signal amplification techniques, which are environmentally sensitive and require additional fuel DNA or enzymes, leading to increased cost and energy consumption.

Method used

A detection method using Janus platinum nanozyme-enhanced tyramide signal amplification probes involves preparing Janus platinum nanoparticles, labeling them with reporter nucleic acid, and using tyramine-modified nanoparticles for signal amplification through nucleic acid hybridization, enabling sensitive and specific detection of myocardial microRNA-155.

Benefits of technology

The method achieves highly sensitive, specific, and high-throughput detection of myocardial microRNA-155 with improved sensitivity and stability, overcoming the limitations of traditional methods by utilizing the catalytic properties of Janus platinum nanozymes for efficient signal amplification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061131A_ABST
    Figure CN119061131A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting low-abundance myocardial MicroRNA-155 based on a tyramine signal amplification probe enhanced by Janus platinum nano enzyme. Janus platinum nano particles are formed by assembling platinum nano particles and silicon dioxide under a mild condition and have relatively high catalytic activity. The invention further discloses a method for detecting the low-abundance myocardial MicroRNA-155 based on the tyramine signal amplification probe enhanced by the Janus platinum nano enzyme. Quantitative detection and analysis are carried out on the myocardial microRNA-155 by combining the specificity of nucleic acid hybridization reaction and taking tyramine modified platinum nanoparticles as a signal amplification enhancer. The method comprises the following steps: carrying out surface amination on Janus platinum nano-enzyme, preparing a nucleic acid probe labeled by the Janus platinum nano-enzyme, preparing a tyramine modified platinum nano-particle signal amplification enhancer, and establishing the tyramine signal amplification probe enhanced by the Janus platinum nano-enzyme to accurately measure the content of the low-abundance myocardial MicroRNA-155. The detection method disclosed by the invention is simple to operate, high in sensitivity and strong in specificity, and can realize high-throughput nondestructive detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of construction of nanozyme-enhanced tyramine signal system and quantitative detection of low-abundance myocardial microRNA-155, and specifically relates to a detection method for detecting low-abundance myocardial microRNA-155 based on a tyramine signal amplification probe enhanced by Janus platinum nanozyme. Background Art

[0002] Acute myocarditis (AM) is a myocardial injury disease with complex etiology and a wide range of clinical manifestations. In acute myocarditis, excessive or uncontrolled inflammatory response leads to myocardial damage and dysfunction. An increasing number of studies have shown that microRNA plays a vital role in the pathogenesis of acute myocarditis. In particular, our previous studies found that microRNA-155 has a high accuracy in the diagnosis and prognosis of AM. Therefore, the establishment of a reliable and sensitive microRNA-155 sensing platform will help the early diagnosis and treatment of AM, which has important practical significance for the health of the whole people.

[0003] Tyramide signal amplification (TSA) is a powerful horseradish peroxidase-mediated amplification method. The TSA system consists of hydrogen peroxide, tyramide, and horseradish peroxidase. When hydrogen peroxide is present, tyramide is converted into active intermediates by horseradish peroxidase. These tyramide intermediates then covalently bind to tyrosine and tryptophan in proteins. Therefore, in the TSA process, various labels functionalized with tyramide or tyrosine can be used to achieve signal amplification methods based on Raman enhancement, immunoassay, colorimetric assay, fluorescence assay, and electrochemical assay. Therefore, the TSA technique has been proven to be an efficient probe amplification method. However, due to the environmental sensitivity of biological enzymes, the TSA technique has the problem of high nonspecific adsorption.

[0004] Janus nanozymes are environmentally stable nano-mimetic enzymes with excellent catalytic properties. Janus nanoparticles are heterogeneous materials that integrate two or more functional units into a single structure. These properties have been reported in various fields to endow Janus nanoparticles with tunable asymmetric components. Compared with single-component nanoparticles, Janus nanostructures usually exhibit two or more properties without mutual influence. These unique and tunable advantages enable the preparation of multifunctional Janus nanoparticles on demand through simple combinations. Therefore, the functionalized design of Janus nanoprobes has great potential in the application of ultrasensitive biosensor platforms.

[0005] Currently, quantitative reverse transcription polymerase chain reaction (qRT-PCR) technology is considered the gold standard for highly sensitive quantitative detection of microRNA. However, qRT-PCR-based methods usually involve complex molecular biology design and strict temperature-controlled amplification procedures. Notably, DNA-functionalized nanoparticles have attracted increasing interest as reporter probes in RNA / DNA detection. Nanosensors based on chemiluminescence, fluorescence, and electrochemiluminescence have made great progress in the quantitative detection of microRNA. Although these nanoprobes provide a platform for the detection of microRNA, DNA-modified single-component nanoprobes still face limited luminescence intensity and effective proton transfer efficiency, making it difficult to achieve ultrasensitive microRNA detection. In addition, numerous signal amplification strategies still require the introduction of additional fuel DNA or DNA enzymes to extend the nucleic acid chain, which increases the cost and energy consumption of the sensor and is prone to nonspecific reactions.

[0006] To this end, we proposed to prepare a detection method based on Janus platinum nanozyme-enhanced tyramide signal amplification probe to detect low-abundance myocardial MicroRNA-155 to solve the above problems. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide a detection method for detecting low-abundance myocardial MicroRNA-155 based on a tyramide signal amplification probe enhanced by Janus platinum nanozyme.

[0008] The objective of the present invention is achieved through the following technical solutions:

[0009] A detection method for detecting low-abundance myocardial MicroRNA-155 based on a Janus platinum nanozyme-enhanced tyramide signal amplification probe comprises the following steps:

[0010] a. Preparation of Janus platinum nanoparticles;

[0011] b. Preparation of reporter nucleic acid labeled Janus platinum nanoparticles;

[0012] c. Preparation of tyramine-modified platinum nanoparticles;

[0013] d. The microRNA-155 capture strand was coated in a 96-well plate, and different concentrations of microRNA-155 standards were added after blocking. Janus platinum nanoparticles labeled with reporter nucleic acid were added after capture. Tyramide-modified platinum nanoparticles were added after washing to establish a Janus platinum nanozyme-enhanced tyramide signal amplification strategy for quantifying myocardial microRNA-155.

[0014] e. Draw a standard curve with the logarithm of the concentration of microRNA-155 standard as the horizontal axis and the absorbance intensity value as the vertical axis, so as to quantitatively detect the concentration of microRNA-155.

[0015] The linear equation of the standard curve is A=1.44+0.381 gC, where A represents the UV absorbance intensity and C represents the concentration of microRNA-155. Correlation coefficient R 2 =0.997, the linear range is 1pM-10nM, and the detection limit is 19fM.

[0016] The step a specifically comprises the following steps:

[0017] a-1. Preparation of 5nm platinum nanoparticles: First, quickly add 0.59-0.85mL, 0.05-0.07M citric acid and 1% sodium citrate solution to 27-30mL boiling chloroplatinic acid (0.016-0.020M) solution and keep for 1-5min. Then, add 0.15-0.20mL of a solution containing sodium borohydride (0.08%-0.10%, w / v), sodium citrate (1%-2%, w / v) and citric acid (0.05%-1.5%, w / v) to the above solution and continue boiling for 10-20min. After cooling to room temperature, a seed solution with a particle size of about 5nm is obtained for use;

[0018] a-2. Preparation of 28nm platinum nanoparticles: Take 5nm seed solution and add it to 29-30mL of deionized water and stir. Add 0.576-0.650mL of chloroplatinic acid solution (0.019-0.020M), 0.5mL of ascorbic acid (1.25%-2.5%, w / v) and sodium citrate (1%-1.5%, w / v) solution to the above solution and stir at room temperature for 10-15min. Heat the system to boiling and keep it for 30min. Cool to room temperature and store at 4℃.

[0019] a-3. Preparation of Janus platinum nanoparticles: Add 0.5-1.5mL, 0.05-0.08M hexadecyltrimethylammonium bromide to 0.44-0.88pM 28 nmPt NPs solution and stir slowly for 15-30min. Add 0.45-0.65mL of ammonia water under continuous stirring, continue stirring for 15-30min, then dropwise add 0.025-0.045mL of tetraethyl silicate and react at room temperature for 5-8h. After the reaction is completed, add ethanol to wash three times and disperse in anhydrous ethanol for later use.

[0020] In the step a, 5 and 28 nm platinum nanoparticles are first synthesized according to a hydrothermal method, and the 28 nm platinum nanoparticles are used as precursor seeds. The well-defined, monodispersed Janus platinum nanoparticles are prepared under mild conditions at room temperature by a gel sol method. Compared with the traditional preparation method of Janus nanoparticles, this method has the technical advantages of mild conditions and a shorter preparation cycle.

[0021] The step b specifically comprises the following steps:

[0022] b-1. Amination of Janus platinum nanoparticles: Add 2-4 mL of Janus platinum nanoparticle ethanol solution to 4-6 mL of anhydrous ethanol. After ultrasonic dispersion, add 0.005-0.009 mL of aminotrimethoxysilane and stir vigorously at room temperature. After the reaction is complete, centrifuge, wash three times with anhydrous ethanol, and freeze-dry for later use;

[0023] b-2. Preparation of reporter nucleic acid labeled Janus platinum nanoparticles: 1-5 mg of Janus platinum nanozyme was washed three times with PBS and fully suspended in 1-3 mL of PBS. 0.2-0.5 mL, 0.015-0.025 mM thiol-modified reporter nucleic acid was slowly added dropwise to the above solution, stirred overnight at 4°C, and washed three times with PBS for use.

[0024] In the step b, 28 nm Janus platinum nanoparticles are first aminated, and aminotrimethoxysilane is used to introduce amino groups on the surface of the silicon component of the Janus platinum nanoparticles at room temperature through a gel sol method; the reporter nucleic acid is further directionally labeled on the surface of the platinum component of the Janus platinum nanoparticles using a platinum-sulfur bond; this method increases the aqueous solution dispersibility of the Janus platinum nanoparticles and the technical advantage of directionally labeling the reporter nucleic acid on the surface of the Janus platinum nanoparticles.

[0025] The step c comprises the following steps:

[0026] c. First, heat 30-50 mL of 0.02-0.05 M chloroplatinic acid to boiling, quickly add 0.50-0.80 mL of 0.05 M-0.1 M tyrosine and keep the reaction for 1-10 min. Then, add 0.20-0.50 mL of an aqueous solution containing sodium borohydride (0.08%-0.10%, w / v) to the above solution and continue boiling for 10-30 min. After cooling to room temperature, obtain a tyrosine-modified platinum nanoparticle solution for use;

[0027] In step c, the tyramine functional molecules are firstly directly modified onto the surface of the platinum nanoparticles, which has the technical advantage of being label-free.

[0028] The step d specifically comprises the following steps:

[0029] d-1. Microplate modification: After treating the plate wells with anhydrous ethanol, potassium hydroxide and aminotrimethoxysilane, add 80-100 μL of 0.015-0.020 mM aldehyde-modified capture nucleic acid to each well, incubate at room temperature for 4-6 hours, then add 100-200 μL of 1%-2% bovine serum albumin to each well and incubate in a 37°C oven for 1-2 hours;

[0030] d-2. Add standard samples: After washing with PBS solution for 3 times, add different concentrations of microRNA-155 standard to each well and incubate in a 37°C oven for 1-2 hours;

[0031] d-3. Add reporter probe: add 80-100 μL of Janus platinum nanoparticles modified with reporter nucleic acid to each well, incubate in a 37°C oven for 1-2 hours, wash, add the same concentration of tyramide-modified platinum nanoparticles and hydrogen peroxide, and incubate at 37°C for 10-30 minutes;

[0032] d-4. Detection: Wash with PBS solution three times to remove unbound platinum nanoparticles, add colorimetric solution, and measure the absorbance intensity value of each well at 490 nm using a multifunctional microplate reader.

[0033] In the step d, the 96-well plate is firstly amino-functionalized, and at room temperature, the capture probe modified with aldehyde groups is anchored through the amino groups on the surface of the plate wells; microRNA-155 is enriched by nucleic acid hybridization reaction between microRNA-155 and the capture probe and the reporter probe; in the presence of hydrogen peroxide, tyramide-modified platinum nanoparticles are infinitely assembled on the Janus platinum surface. Compared with the traditional bio-enzyme method, the method introduces Janus nanozymes to increase the stability of the system, realize efficient signal amplification, and has the technical advantage of improving detection sensitivity.

[0034] Compared with the prior art, the beneficial effects of the present invention are as follows: Based on the easy modification of the surface of Janus platinum nanozymes and their high-efficiency catalytic enzyme-mimicking performance of tyramine polymerization, this method improves the sensitivity of MicroRNA-155 detection. That is, by preparing oligonucleotide-modified Janus platinum nanoparticles and tyramine-modified platinum nanoparticles, combined with the specificity of nucleic acid hybridization reactions, highly sensitive quantitative analysis of myocardial MicroRNA-155 is performed. The method is easy to operate, highly sensitive, highly specific, and can achieve high throughput, precise targeting, and non-destructive detection, as follows:

[0035] (1) A simpler and faster method was used to prepare Janus platinum nanoparticles as signal amplification carriers, laying the foundation for the directional labeling of reporter nucleic acid molecules;

[0036] (2) Using tyrosine as a protective agent, tyramide-modified platinum nanoparticles were prepared in one step, providing a new strategy for nanozyme signal amplification;

[0037] (3) The use of aptamer-directed modified Janus platinum nanoparticles, tyramide-modified platinum nanoparticles and nucleic acid hybridization reactions provided a new method for the highly sensitive detection of myocardial microRNA-155.

[0038] (4) This method is easy to operate, has high sensitivity and specificity, and can achieve high-throughput nondestructive testing. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 The standard curve is established with the logarithm of the concentration of the microRNA-155 standard as the horizontal axis and the absorbance intensity value as the vertical axis. DETAILED DESCRIPTION

[0040] The following will describe the implementation methods of the present application in detail with the help of accompanying drawings and examples, so that the implementation process of how the present application uses technical means to solve technical problems and achieve technical effects can be fully understood and implemented accordingly.

[0041] The nanozymes used in the experiment were homemade in the laboratory, and other reagents can be purchased from commercial manufacturers.

[0042] The preparation method of the buffer solution involved in the present invention is:

[0043] Phosphate buffer solution (1 mM, pH = 7.4): weigh 0.4 g of sodium chloride, 0.0.05 g of potassium chloride, 0.025 g of sodium dihydrogen phosphate, and 0.16 g of disodium hydrogen phosphate, dissolve in secondary deionized water and make up to 50 mL.

[0044] Carbonate buffer (0.5 mM, pH = 9.6): Weigh 1.80 g of sodium bicarbonate and 0.80 g of sodium carbonate, dissolve in distilled water and make up to 50 mL.

[0045] Example 1

[0046] A method for detecting low-abundance myocardial microRNA-155 based on a Janus platinum nanozyme-enhanced tyramide signal amplification probe comprises the following steps:

[0047] a. Preparation of Janus platinum nanoparticles:

[0048] a-1. Preparation of 5nm platinum nanoparticles: First, quickly add 0.59-0.85mL, 0.05-0.07M citric acid and 1% sodium citrate solution to 27-30mL boiling chloroplatinic acid (0.016-0.020M) solution and keep for 1-5min. Then, add 0.15-0.20mL of a solution containing sodium borohydride (0.08%-0.10%, w / v), sodium citrate (1%-2%, w / v) and citric acid (0.05%-1.5%, w / v) to the above solution and continue boiling for 10-20min. After cooling to room temperature, a seed solution with a particle size of about 5nm is obtained for use;

[0049] a-2. Preparation of 28nm platinum nanoparticles: Take 5nm seed solution and add it to 29-30mL of deionized water and stir. Add 0.576-0.650mL of chloroplatinic acid solution (0.019-0.020M), 0.5mL of ascorbic acid (1.25%-2.5%, w / v) and sodium citrate (1%-1.5%, w / v) solution to the above solution and stir at room temperature for 10-15min. Heat the system to boiling and keep it for 30min. Cool to room temperature and store at 4℃.

[0050] a-3. Preparation of Janus platinum nanoparticles: Add 0.5-1.5 mL of 0.05-0.08 M hexadecyl trimethyl ammonium bromide to 0.44-0.88 pM 28 nm Pt NPs solution and stir slowly for 15-30 min. Add 0.45-0.65 mL of ammonia water under continuous stirring, continue stirring for 15-30 min, then dropwise add 0.025-0.045 mL of tetraethyl silicate and react at room temperature for 5-8 h. After the reaction is completed, add ethanol to wash three times and disperse in anhydrous ethanol for later use.

[0051] b. Preparation of reporter nucleic acid labeled Janus platinum nanoparticles:

[0052] b-1. Amination of Janus platinum nanoparticles: Add 2-4 mL of Janus platinum nanoparticle ethanol solution to 4-6 mL of anhydrous ethanol. After ultrasonic dispersion, add 0.005-0.009 mL of aminotrimethoxysilane and stir vigorously at room temperature. After the reaction is complete, centrifuge, wash three times with anhydrous ethanol, and freeze-dry for later use;

[0053] b-2. Preparation of reporter nucleic acid labeled Janus platinum nanoparticles: 1-5 mg of Janus platinum nanozyme was washed three times with PBS and fully suspended in 1-3 mL of PBS. 0.2-0.5 mL, 0.015-0.025 mM thiol-modified reporter nucleic acid was slowly added dropwise to the above solution, stirred overnight at 4°C, and washed three times with PBS for use.

[0054] c. Preparation of tyramine-modified platinum nanoparticles:

[0055] c-1. First, heat 30-50 mL of 0.02-0.05 M chloroplatinic acid to boiling, quickly add 0.50-0.80 mL of 0.05 M-0.1 M tyrosine and keep the reaction for 1-10 min. Then, add 0.20-0.50 mL of an aqueous solution containing sodium borohydride (0.08%-0.10%, w / v) to the above solution and continue boiling for 10-30 min. After cooling to room temperature, obtain a tyrosine-modified platinum nanoparticle solution for use;

[0056] d. After the 96-well plate is treated, the captured nucleic acid is covalently bound, and after blocking, different concentrations of microRNA-155 standards are added. Janus platinum nanoparticles modified with reporter nucleic acid are used as reporter probes, and tyramide-modified platinum nanoparticles are used as enhancers to establish a sandwich nucleic acid hybridization reaction for highly sensitive quantitative detection of microRNA-155. By utilizing the unlimited self-assembly characteristics of tyramide-modified platinum nanozymes on the Janus structure and the high specificity of nucleic acid hybridization cross-reaction, the purpose of quantitative detection of microRNA-155 is achieved through the signal of substrate color development catalyzed by nucleic acid hybridization complexes. This method has a lower detection limit and higher sensitivity than the detection of biological enzymes.

[0057] The step d specifically comprises the following steps:

[0058] d-1. Microplate modification: After treating the plate wells with anhydrous ethanol, potassium hydroxide and aminotrimethoxysilane, add 80-100 μL of 0.015-0.020 mM aldehyde-modified capture nucleic acid to each well, incubate at room temperature for 4-6 hours, then add 100-200 μL of 1%-2% bovine serum albumin to each well and incubate in a 37°C oven for 1-2 hours;

[0059] d-2. Add standard samples: After washing with PBS solution for 3 times, add different concentrations of microRNA-155 standard to each well and incubate in a 37°C oven for 1-2 hours;

[0060] d-3. Add reporter probe: add 80-100 μL of Janus platinum nanoparticles modified with reporter nucleic acid to each well, incubate in a 37°C oven for 1-2 hours, wash, add the same concentration of tyramide-modified platinum nanoparticles and hydrogen peroxide, and incubate at 37°C for 10-30 minutes;

[0061] d-4. Detection: Wash with PBS solution three times to remove unbound platinum nanoparticles, add colorimetric solution, and measure the absorbance intensity value of each well at 490 nm using a multifunctional microplate reader.

[0062] e. A standard curve was established with the logarithm of the concentration of the microRNA-155 standard solution as the horizontal axis and the absorbance intensity as the vertical axis. The obtained standard curve is shown in the figure below. Figure 1 As shown, the linear equation of the standard curve is: A = 1.44 + 0.38lgC, where A is the absorbance intensity value, C is the concentration of microRNA-155, and the correlation coefficient R 2 =0.997, linear range is 1pM-10nM, detection limit is 19fM;

[0063] Repeat the above steps, except that the microRNA-155 standard solutions of different concentrations in step d-2 are replaced with microRNA-155 test samples of unknown concentration, and then the absorbance intensity of each well at 490 nm is measured on a microplate reader, and the average absorbance intensity is calculated. The concentration of microRNA-155 in the test sample can be calculated based on the above standard curve.

[0064] In summary, the above are only preferred embodiments of the present invention and are not intended to limit the present invention in any form. Any simple modifications or equivalent changes made to the above embodiments based on the technical essence of the present invention fall within the protection scope of the present invention.

[0065] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any simple modification, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention are within the scope of the technical solution of the present invention.

Claims

1. A detection method for low-abundance myocardial MicroRNA-155 based on Janus platinum nanozyme-enhanced tyramide signal amplification probe, Features: The steps include: S1, Preparation of Janus platinum nanoparticles; S2, preparation of reporter nucleic acid labeled Janus platinum nanoparticles; S3, preparation of tyramine-modified platinum nanoparticles; S4, the microRNA-155 capture nucleic acid sequence was coated in a 96-well plate, and different concentrations of microRNA-155 standards were added after blocking, Janus platinum nanoparticles labeled with reporter nucleic acid were added after capture, and tyramide-modified platinum nanoparticles were added after washing to establish the Janus platinum nanozyme-enhanced tyramide signal amplification strategy for quantifying myocardial microRNA-155; S5. Draw a standard curve with the logarithm of the concentration of the microRNA-155 standard as the horizontal axis and the absorbance intensity value as the vertical axis, so as to quantitatively detect the concentration of microRNA-155.

2. The detection method for detecting low-abundance myocardial MicroRNA-155 based on the Janus platinum nanozyme-enhanced tyramide signal amplification probe according to claim 1, It is characterized in that The step S1 specifically includes the following steps: S1.1, amination of Janus platinum nanoparticles: add anhydrous ethanol to the ethanol solution of Janus platinum nanoparticles, disperse by ultrasonication, add aminotrimethoxysilane, stir vigorously at room temperature, centrifuge after the reaction, wash three times with anhydrous ethanol, freeze-dry and set aside; S1.

2. Preparation of Janus platinum nanoparticles labeled with reporter nucleic acid: Wash Janus platinum nanozyme three times with PBS, fully suspend it in PBS, slowly add thiol-modified reporter nucleic acid to the above solution, stir overnight at 4°C, wash it three times with PBS and set aside.

3. The detection method for detecting low-abundance myocardial MicroRNA-155 based on the Janus platinum nanozyme-enhanced tyramide signal amplification probe according to claim 3, Features: As stated, In step S1.1, 2-4 mL of platinum nanoparticle ethanol solution, 4-6 mL of anhydrous ethanol, and 0.005-0.009 mL of aminotrimethoxysilane are taken; In step S1.2, 1-5 mg of Janus platinum nanozyme, 1-3 mL of PBS, and 0.2-0.5 mL and 0.015-0.025 mM of thiol-modified reporter nucleic acid are taken.

4. The method for detecting low-abundance myocardial MicroRNA-155 based on the Janus platinum nanozyme-enhanced tyramide signal amplification probe according to claim 1, Features: The step S3 is specifically as follows: S3.

1. First, heat chloroplatinic acid to boiling state, quickly add tyrosine and keep the reaction for 1-10 minutes; S3.

2. Add an aqueous solution containing sodium borohydride to the above solution and continue boiling for 10-30 minutes. After cooling to room temperature, obtain a tyrosine-modified platinum nanoparticle solution for use.

5. The method for detecting low-abundance myocardial MicroRNA-155 based on the Janus platinum nanozyme-enhanced tyramide signal amplification probe according to claim 4, Features: As stated, In step 3.1, take 30-50 mL of chloroplatinic acid, 0.02-0.05 M, and take 0.50-0.80 mL of tyrosine, 0.05 M-0.1 M In step 3.2, 0.20-0.50 mL of the aqueous solution and 0.08%-0.10% of sodium borohydride are used, w / v.

6. The method for detecting low-abundance myocardial MicroRNA-155 based on the Janus platinum nanozyme-enhanced tyramide signal amplification probe according to claim 1, Features: The specific steps of step S4 are as follows: S4.1, microplate modification: after treating the wells with anhydrous ethanol, potassium hydroxide and aminotrimethoxysilane, add 80-100 μL of 0.015-0.020 mM aldehyde-modified capture nucleic acid to each well, incubate at room temperature for 4-6 hours, then add 100-200 μL of 1%-2% bovine serum albumin to each well and incubate in a 37°C oven for 1-2 hours; S4.

2. Add standard samples: After washing with PBS solution for 3 times, add different concentrations of microRNA-155 standard to each well and incubate in a 37°C oven for 1-2 hours; S4.3, adding reporter probes: add 80-100 μL of Janus platinum nanoparticles modified with reporter nucleic acid to each well, incubate in an oven at 37°C for 1-2 hours, wash, add the same concentration of tyramide-modified platinum nanoparticles and hydrogen peroxide, and incubate at 37°C for 10-30 minutes; S4.

4. Detection: Wash with PBS solution three times to remove unbound platinum nanoparticles, add colorimetric solution, and measure the absorbance intensity value of each well at 490 nm using a multifunctional microplate reader.

7. The preparation method according to any one of claims 1 to 4, It is characterized in that The linear equation of the standard curve in step g is A=1.44+0.381gC, where A is the absorbance intensity value and C is the concentration of microRNA-155.

8. The method for detecting low-abundance myocardial MicroRNA-155 based on the Janus platinum nanozyme-enhanced tyramide signal amplification probe according to claim 1, Features: The linear equation of the standard curve in step S5 is A=1.44+0.381gC, where A is the absorbance intensity value and C is the concentration of microRNA-155.

9. The method for detecting low-abundance myocardial MicroRNA-155 based on the Janus platinum nanozyme-enhanced tyramide signal amplification probe according to claim 1, Features: The correlation coefficient R of the standard curve 2 =0.997, the linear range is 1pM-10nM, and the detection limit is 19fM.

Citation Information

Cited By

  • Nucleic acid assembly amplification chemiluminescence detection method based on double antibodies

    CN120948806A

  • Immunosensor for detecting cardiac troponin I as well as preparation method, use method and application of immunosensor

    CN121347830A